Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
MITOTANE
HRA PHARMA RARE DISEASES
L01XX23
MITOTANE
500MG
TABLET
MITOTANE 500MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0113395001; AHFS:
APPROVED
2020-04-03
_LYSODREN Tablets, 500 mg _ _Page 1 of 25_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR LYSODREN® Mitotane tablets Tablets, 500 mg, oral administration Antineoplastic Agent HRA Pharma Rare Diseases 200 Avenue de Paris Châtillon, France 92320 Date of Initial Authorization: DEC 31, 1979 Date of Revision: SEPT 25, 2023 Submission Control Number: 275256 _ _ _LYSODREN 500 mg Tablets _ _Page 2 of 25_ RECENT MAJOR LABEL CHANGES 4 Dosage and Administration, 4.1 Dosing Considerations 09/2023 4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment 09/2023 4 Dosage and Administration, 4.4 Administration 09/2023 7 Warnings and Precautions, Endocrine and Metabolism 09/2023 7 Warnings and Precautions, General 09/2023 7 Warnings and Precautions, Hematologic 09/2023 7 Warnings and Precautions, Hepatic/Biliary/Pancreatic 09/2023 7 Warnings and Precautions, Monitoring and Laboratory Tests 09/2023 7 Warnings and Precautions, Peri-Operative Considerations 09/2023 7 Warnings and Precautions, Renal 09/2023 7 Warnings and Precautions, 7.1.1 Pregnant Women 09/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics (<18 years of age) ................................................................................... 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................... Baca dokumen lengkap